Nanoparticle display of prefusion coronavirus spike elicits S1-focused cross-reactive antibody response against diverse coronavirus subgenera

Geoffrey B. Hutchinson, Olubukola M. Abiona, Cynthia T. Ziwawo, Anne P. Werner, Daniel Ellis, Yaroslav Tsybovsky, Sarah R. Leist, Charis Palandjian, Ande West, Ethan J. Fritch, Nianshuang Wang, Daniel Wrapp, Seyhan Boyoglu-Barnum, George Ueda, David Baker, Masaru Kanekiyo, Jason S. McLellan, Ralph S. Baric, Neil P. King, Barney S. Graham () and Kizzmekia S. Corbett-Helaire ()
Additional contact information
Geoffrey B. Hutchinson: National Institutes of Health
Olubukola M. Abiona: National Institutes of Health
Cynthia T. Ziwawo: National Institutes of Health
Anne P. Werner: National Institutes of Health
Daniel Ellis: University of Washington School of Medicine
Yaroslav Tsybovsky: Frederick National Laboratory for Cancer Research
Sarah R. Leist: University of North Carolina at Chapel Hill
Charis Palandjian: Harvard T.H. Chan School of Public Health
Ande West: University of North Carolina at Chapel Hill
Ethan J. Fritch: University of North Carolina at Chapel Hill
Nianshuang Wang: University of Texas at Austin
Daniel Wrapp: University of Texas at Austin
Seyhan Boyoglu-Barnum: National Institutes of Health
George Ueda: University of Washington School of Medicine
David Baker: University of Washington School of Medicine
Masaru Kanekiyo: National Institutes of Health
Jason S. McLellan: University of Texas at Austin
Ralph S. Baric: University of North Carolina at Chapel Hill
Neil P. King: University of Washington School of Medicine
Barney S. Graham: National Institutes of Health
Kizzmekia S. Corbett-Helaire: National Institutes of Health

Nature Communications, 2023, vol. 14, issue 1, 1-11

Abstract: Abstract Multivalent antigen display is a fast-growing area of interest toward broadly protective vaccines. Current nanoparticle-based vaccine candidates demonstrate the ability to confer antibody-mediated immunity against divergent strains of notably mutable viruses. In coronaviruses, this work is predominantly aimed at targeting conserved epitopes of the receptor binding domain. However, targeting conserved non-RBD epitopes could limit the potential for antigenic escape. To explore new potential targets, we engineered protein nanoparticles displaying coronavirus prefusion-stabilized spike (CoV_S-2P) trimers derived from MERS-CoV, SARS-CoV-1, SARS-CoV-2, hCoV-HKU1, and hCoV-OC43 and assessed their immunogenicity in female mice. Monotypic SARS-1 nanoparticles elicit cross-neutralizing antibodies against MERS-CoV and protect against MERS-CoV challenge. MERS and SARS nanoparticles elicit S1-focused antibodies, revealing a conserved site on the S N-terminal domain. Moreover, mosaic nanoparticles co-displaying distinct CoV_S-2P trimers elicit antibody responses to distant cross-group antigens and protect male and female mice against MERS-CoV challenge. Our findings will inform further efforts toward the development of pan-coronavirus vaccines.

Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (1)

Downloads: (external link)
https://www.nature.com/articles/s41467-023-41661-4 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:14:y:2023:i:1:d:10.1038_s41467-023-41661-4

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-023-41661-4

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().